Lefkowitz R J, Mullikin D, Caron M G
J Biol Chem. 1976 Aug 10;251(15):4686-92.
Guanyl-5'-yl imidodiphosphate (Gpp(NH)p), GTP, and other purine nucleotides selectively decrease the binding affinity of the beta-adrenergic receptors of frog erythrocyte membranes for beta-adrenergic agonists but not antagonists. Shifts in binding affinity were assessed by determining the ability of unlabeled ligands to compete with (-)-[3H]dihydroalprenolol for the membrane-bound receptors. The magnitude of the"right" shift in the binding displacement curve for any of 13 ligands tested was directly related to the intrinsic activity (maximal stimulatory capacity) of that agent for stimulation of the frog erythrocyte membrane adenylate cyclase. Thus, Gpp(NH)p-induced shifts in binding affinity were greatest for full agonists such as isoproterenol, intermediate for partial agonists such as soterenol, and no shifts were observed for antagonists such as propranolol. Shifts in binding affinity were observed only in preparations where agonist binding to the receptors leads to "coupling" of the receptors with adenylate cyclase. In solubilized preparations where the beta-adrenergic receptors and adenylate cyclase are functionally "uncoupled", Gpp(NH)p did not cause right shifts in agonist receptor binding displacement curves. In particulate preparations the Km of Gpp(NH)p for stimulation of adenylate cyclase was identical with that for its effect on beta-adrenergic agonist binding affinity, 1 to 2 muM. Moreover, the ability of several other nucleotides to cause shifts in receptor binding affinity directly paralleled their previously determined affinities for the nucleotide regulatory sites on adenylate cyclase. Gpp(NH)p also shifted agonist dose-response curves for stimulation of adenylate cyclase, but to the left. As with the effects on the receptor binding curves, the effects of Gpp(NH)p on the "apparent affinities" of agonists for enzyme stimulation were directly related to their intrinsic activities. Gpp(NH)p also markedly increased the intrinsic activity of partial agonists. These results appear to indicate that conformational alterations in adenylate cyclase caused by occupation of nucleotide regulatory sites by Gpp(NH)p are capable of inducing alterations in the beta-adrenergic receptors. These receptor alterations are induced only when the receptors are "coupled" to the enzyme by virtue of agonist binding. The nucleotide-altered conformation of the beta-adrenergic receptors is characterized by decreased binding affinity for agonist but increased functional efficacy in stimulating the enzyme.
鸟苷-5'-基亚氨基二磷酸(Gpp(NH)p)、GTP及其他嘌呤核苷酸可选择性降低蛙红细胞膜β-肾上腺素能受体对β-肾上腺素能激动剂而非拮抗剂的结合亲和力。通过测定未标记配体与(-)-[3H]二氢阿普洛尔竞争膜结合受体的能力来评估结合亲和力的变化。在所测试的13种配体中,任何一种配体结合位移曲线的“右”移幅度都与该试剂刺激蛙红细胞膜腺苷酸环化酶的内在活性(最大刺激能力)直接相关。因此,Gpp(NH)p诱导的结合亲和力变化对异丙肾上腺素等完全激动剂最大,对索特雷诺等部分激动剂中等,而对普萘洛尔等拮抗剂则未观察到变化。仅在激动剂与受体结合导致受体与腺苷酸环化酶“偶联”的制剂中观察到结合亲和力的变化。在β-肾上腺素能受体与腺苷酸环化酶功能上“解偶联”的溶解制剂中,Gpp(NH)p不会引起激动剂受体结合位移曲线的右移。在颗粒制剂中,Gpp(NH)p刺激腺苷酸环化酶的Km与其对β-肾上腺素能激动剂结合亲和力的影响相同,为1至2μM。此外,其他几种核苷酸引起受体结合亲和力变化的能力与其先前确定的对腺苷酸环化酶核苷酸调节位点的亲和力直接平行。Gpp(NH)p还使刺激腺苷酸环化酶的激动剂剂量-反应曲线向左移动。与对受体结合曲线的影响一样,Gpp(NH)p对激动剂刺激酶的“表观亲和力”的影响与它们的内在活性直接相关。Gpp(NH)p还显著增加了部分激动剂的内在活性。这些结果似乎表明,Gpp(NH)p占据核苷酸调节位点引起的腺苷酸环化酶构象改变能够诱导β-肾上腺素能受体的改变。仅当受体通过激动剂结合与酶“偶联”时才会诱导这些受体改变。β-肾上腺素能受体的核苷酸改变构象的特征是对激动剂的结合亲和力降低,但刺激酶的功能效力增加。